Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM SR versus VERARING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM SR versus VERARING.
CARDIZEM SR vs VERARING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Not available
Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.
No established standard dosing. Veraring is not a recognized pharmaceutical agent.
None Documented
None Documented
3.0-4.5 hours for diltiazem; metabolites (e.g., desacetyldiltiazem) up to 10 hours. Clinical context: dosing interval adjustment in hepatic impairment.
Terminal elimination half-life: 4.5 hours (range 3.5-6.0 hours). Clinical context: Steady state achieved within 24 hours; no accumulation with normal renal function.
Renal: 2-4% unchanged; hepatic metabolism: ~60-70% (including active metabolites); fecal: ~30-40%.
Renal elimination of unchanged drug and metabolites: 70% (60% unchanged, 40% as glucuronide conjugate); biliary/fecal: 30% (primarily metabolites).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker